COPENHAGEN (Reuters) – Novo Nordisk said on Wednesday it will recognize an impairment charge of about DKK 5.7 billion ($816.72 million) in the second quarter of 2024 after its phase 3 CLARION-CKD study did not reach the primary endpoint.
Novo has decided to stop the CLARION-CKD study because it did not meet the primary endpoint of change in systolic blood pressure from baseline to week 12, the company said in a statement.
The deterioration is due to ocedurenon, a drug for uncontrolled hypertension with potential use in cardiovascular and kidney diseases that Novo acquired from KBP Biosciences in October 2023, the Danish pharmaceutical giant said.
($1 = 6.9791 Danish kroner)